The DOI matches its Crossref record; 61 of the 61 references it cites were found in a registry or an index.
Virus-like particles: Passport to immune recognition
Open accessAbstract
Virus-like particles (VLPs) are formed by the self-assembly of envelope and/or capsid proteins from many viruses. In many cases such VLPs have structural characteristics and antigenicity similar to the parental virus, and some have already proven successful as vaccines against the cognate virus infection. The structural components of some VLPs have also proven amenable to the insertion or fusion of foreign antigenic sequences, allowing the production of chimeric VLPs exposing the foreign antigen on their surface. Other VLPs have been used as carriers for foreign antigens, including non-protein antigens, via chemical conjugation. This review outlines some of the advantages, disadvantages, and technical considerations for the use of a wide range of VLP systems in vaccine development.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Pushko, P., Pumpens, P., & Grens, E. (2013) · Intervirology · doi:10.1159/000346773 · Cited by 5,950
A Controlled Trial of a Human Papillomavirus Type 16 Vaccine
Koutsky, L. A., Ault, K. A., Wheeler, C. M., Brown, D. R., Barr, E., Alvarez, F. B., Chiacchierini, L. M., & Jansen, K. U. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa020586 · Cited by 1,602
Villa, L. L., Costa, R. L., Petta, C. A., Andrade, R. P., Ault, K. A., Giuliano, A. R., Wheeler, C. M., Koutsky, L. A., Malm, C., Lehtinen, M., et al. (2005) · The Lancet Oncology · doi:10.1016/s1470-2045(05)70101-7 · Cited by 1,579
Kirnbauer, R., Booy, F., Cheng, N., Lowy, D. R., & Schiller, J. T. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.24.12180 · Cited by 1,110
Gheysen, D., Jacobs, E., de Foresta, F., Thiriart, C., Francotte, M., Thines, D., & De Wilde, M. (1989) · Cell · doi:10.1016/0092-8674(89)90873-8 · Cited by 747
Human hepatitis B vaccine from recombinant yeast
McAleer, W. J., Buynak, E. B., Maigetter, R. Z., Wampler, D. E., Miller, W. J., & Hilleman, M. R. (1984) · Nature · doi:10.1038/307178a0 · Cited by 739
Beignon, A.-S. (2005) · Journal of Clinical Investigation · doi:10.1172/jci26032 · Cited by 673
Size-Dependent Immunogenicity: Therapeutic and Protective Properties of Nano-Vaccines against Tumors
Fifis, T., Gamvrellis, A., Crimeen-Irwin, B., Pietersz, G. A., Li, J., Mottram, P. L., McKenzie, I. F. C., & Plebanski, M. (2004) · The Journal of Immunology · doi:10.4049/jimmunol.173.5.3148 · Cited by 664
Immunogenicity in humans of a recombinant bacterial antigen delivered in a transgenic potato
Tacket, C. O., Mason, H. S., Losonsky, G., Clements, J. D., Levine, M. M., & Arntzen, C. J. (1998) · Nature Medicine · doi:10.1038/nm0598-607 · Cited by 581
Zhou, J., Sun, X. Y., Stenzel, D. J., & Frazer, I. H. (1991) · Virology · doi:10.1016/0042-6822(91)90772-4 · Cited by 506
Cited by
Bio-inspired, bioengineered and biomimetic drug delivery carriers
Yoo, J.-W., Irvine, D. J., Discher, D. E., & Mitragotri, S. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3499 · Cited by 1,236
Zhao, L., Seth, A., Wibowo, N., Zhao, C.-X., Mitter, N., Yu, C., & Middelberg, A. P. J. (2014) · Vaccine · doi:10.1016/j.vaccine.2013.11.069 · Cited by 919
Virus-like particles in vaccine development
Roldão, A., Mellado, M. C. M., Castilho, L. R., Carrondo, M. J., & Alves, P. M. (2010) · Expert Review of Vaccines · doi:10.1586/erv.10.115 · Cited by 845
Kushnir, N., Streatfield, S. J., & Yusibov, V. (2012) · Vaccine · doi:10.1016/j.vaccine.2012.10.083 · Cited by 587
Nanotechnology in vaccine delivery
Peek, L. J., Middaugh, C. R., & Berkland, C. (2008) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2007.05.017 · Cited by 562
Vaccine delivery using nanoparticles
Gregory, A. E., Titball, R., & Williamson, D. (2013) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2013.00013 · Cited by 561
Nanoparticle Vaccines Against Infectious Diseases
Pati, R., Shevtsov, M., & Sonawane, A. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.02224 · Cited by 514
Ma, J., Bruce, T. J., Jones, E. M., & Cain, K. D. (2019) · Microorganisms · doi:10.3390/microorganisms7110569 · Cited by 424
D’Aoust, M., Couture, M. M. ‐., Charland, N., Trépanier, S., Landry, N., Ors, F., & Vézina, L. (2010) · Plant Biotechnology Journal · doi:10.1111/j.1467-7652.2009.00496.x · Cited by 371
The coming of age of virus-like particle vaccines
Jennings, G. T., & Bachmann, M. F. (2008) · bchm · doi:10.1515/bc.2008.064 · Cited by 369
Self-assembling protein nanoparticles in the design of vaccines
López-Sagaseta, J., Malito, E., Rappuoli, R., & Bottomley, M. J. (2016) · Computational and Structural Biotechnology Journal · doi:10.1016/j.csbj.2015.11.001 · Cited by 353
Artificial cells: from basic science to applications
Xu, C., Hu, S., & Chen, X. (2016) · Materials Today · doi:10.1016/j.mattod.2016.02.020 · Cited by 344
Vaccine adjuvant systems: Enhancing the efficacy of sub-unit protein antigens
Perrie, Y., Mohammed, A. R., Kirby, D. J., McNeil, S. E., & Bramwell, V. W. (2008) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2008.04.036 · Cited by 333
Emerging Concepts and Technologies in Vaccine Development
Brisse, M., Vrba, S. M., Kirk, N., Liang, Y., & Ly, H. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.583077 · Cited by 323
Virus-like particles: flexible platforms for vaccine development
Chackerian, B. (2007) · Expert Review of Vaccines · doi:10.1586/14760584.6.3.381 · Cited by 321
An Overview of Vaccine Adjuvants: Current Evidence and Future Perspectives
Facciolà, A., Visalli, G., Laganà, A., & Di Pietro, A. (2022) · Vaccines · doi:10.3390/vaccines10050819 · Cited by 316
Synthetic biology devices for in vitro and in vivo diagnostics
Slomovic, S., Pardee, K., & Collins, J. J. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1508521112 · Cited by 314
Virus-like particles—universal molecular toolboxes
Ludwig, C., & Wagner, R. (2007) · Current Opinion in Biotechnology · doi:10.1016/j.copbio.2007.10.013 · Cited by 303
Virus-like particle vaccinology, from bench to bedside
Mohsen, M. O., & Bachmann, M. F. (2022) · Cellular & Molecular Immunology · doi:10.1038/s41423-022-00897-8 · Cited by 289
D’Aoust, M., Lavoie, P., Couture, M. M. ‐., Trépanier, S., Guay, J., Dargis, M., Mongrand, S., Landry, N., Ward, B. J., & Vézina, L. (2008) · Plant Biotechnology Journal · doi:10.1111/j.1467-7652.2008.00384.x · Cited by 279
Large-scale production and purification of VLP-based vaccines
Vicente, T., Roldão, A., Peixoto, C., Carrondo, M. J. T., & Alves, P. M. (2011) · Journal of Invertebrate Pathology · doi:10.1016/j.jip.2011.05.004 · Cited by 270
The Art of Engineering Viral Nanoparticles
Pokorski, J. K., & Steinmetz, N. F. (2011) · Molecular Pharmaceutics · doi:10.1021/mp100225y · Cited by 266
Black, M., Trent, A., Tirrell, M., & Olive, C. (2010) · Expert Review of Vaccines · doi:10.1586/erv.09.160 · Cited by 203
Platforms for Production of Protein-Based Vaccines: From Classical to Next-Generation Strategies
Cid, R., & Bolívar, J. (2021) · Biomolecules · doi:10.3390/biom11081072 · Cited by 176
Plant-made polio type 3 stabilized VLPs-a candidate synthetic polio vaccine
Marsian, J., Fox, H., Bahar, M. W., Kotecha, A., Fry, E. E., Stuart, D. I., Macadam, A. J., Rowlands, D. J., & Lomonossoff, G. P. (2017) · Nature Communications · doi:10.1038/s41467-017-00090-w · Cited by 121
Metadata
- Authors
- Grgacic, E. V. L., & Anderson, D. A.
- Venue
- Methods
- Publisher
- Elsevier BV
- Published
- 2006-09
- Volume
- 40
- Issue
- 1
- Pages
- 60-65
- ISSN
- 1046-2023 (ISSN-L)
- OpenAlex
- W2075515367
- Cited by
- 582
- References
- 61
- FWCI
- 6.63
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.